Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

J. Muniz



Author of

  • +

    P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P1.01-047 - Pemetrexed in Treating Advanced NSCLC (ID 2992)

      09:30 - 09:30  |  Author(s): J. Muniz

      • Abstract

      Background:
      In advanced NSCLC, the goal of maintenance therapy is to prolong overall survival of first line platinum based combination chemotherapy. Maintenance Pemetrexed was associated with statistically and clinically significant improvement in both PFS ans OS. Objective was to determine the response rate, progression-free survival (PFS), overall survival (OS).

      Methods:
      Between January 2011 until July 2014, Peruvian patients with advanced NSCLC (IIIB, IVA) received four to six cycles of Carboplatin (AUC 6) - Pemetrexed 500mg/m2 day 1. Patients who achieved a complete response (CR), partial response (PR) o stable diase (SD) were to received maintenance Pemetrexed (500mg/m2 day 1) in 21 day cycles until disease progression. All patients recevied vitamin B12, Folic acid supplement.

      Results:
      83 patients received induction chemotherapy and maintenance therapy, median age was 61 years (26 - 84), > 70 years 15.7%, female:male 1.5, no smoking:smoking 2.6, exposure to wood smoke 25 (30.1%), ECOG 1 98.8%, EC IIIB 8.4%, EC IV 91.6%, hystology Adenocarcinoma 100%. Sites of metastasis: pleural 36 (43.4%), bone 20 (24.1%), brain 7 (8.4%), liver 4 (4.8%). 40 (48.2%) received 4 cycles, 27 (32.5%) 6 cycles of induction chemotherapy; median of cycles of maintenance 5 cycles (1-16). Response to treatment: 4 (4.8%) RC, 42 (50.6%) RP, 30 (36.1%) DS, 7 (8.4%) PD. The median time to progression was 11 months, estimated PFS was 86.5%, 39.6%, 13.8% at 6, 12, 30 months respectively. The estimated OS was 68.8%, 51.4% and 41.5% at 12, 24 and 30 months respectively, median time to OS was 28 months. None variables are significantly associated with OS.

      Conclusion:
      Induction chemotherapy and maintenance therapy with Pemetrexed improves PFS and OS in patients with advanced lung cancer without compromising the quality of life. There is a need for better ways of identifying patients most likely to benefit.